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The transmission of direct-acting antiviral resistance-associated 
substitutions (RAS) could hamper hepatitis C virus (HCV) cure 
rates and elimination efforts. A phylogenetic analysis of 87 men 
who have sex with men recently infected with HCV genotype 
1a placed one-third (28/87) in a large cluster, in which 96% 
 harbored NS5A M28V RAS.
Keywords.  hepatitis C virus; resistant associated substitu-
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In this study we analyzed a population of men who have sex with 
men (MSM) who were mostly also living with human immuno-
deficiency virus (HIV), were diagnosed with a recently acquired 
hepatitis C virus (HCV) genotype 1a infection, and participated 
in 2 trials studying the effectiveness of direct-acting antiviral 
(DAA) therapy. A recent HCV infection is considered to be an 
infection less than 6 months old using criteria that have been 
described elsewhere [1]. In both trials, patients with a recently 
acquired HCV infection were enrolled at 11 HIV treatment sites 
in the Netherlands and Belgium [1, 2]. A  total of 44 individ-
uals received boceprevir, pegylated interferon, and ribavirin 
(2013–2014, Dutch Acute HCV in HIV Study [DAHHS] 1 
study), while 43 were treated with grazoprevir and elbasvir 
(2016–2018, DAHHS 2 study) [1, 2]. We generated whole-
genome sequences based on the Illumina sequencing platform 
from pre-therapy samples in the DAHHS 1 study and NS5A 
and NS5B partial gene sequences using Sanger sequencing in 
DAHHS 2 (for methods, see the Supplementary Data). The 
analysis for resistance-associated substitutions (RAS) in the 
baseline samples showed a very high prevalence of the NS5A 
M28V RAS, which was present in 31 patients (35.6%; 95% con-
fidence interval, 26.4–46.1). This prevalence is substantially 
higher than the 0–6% prevalence described previously in other 
studies, including a study among MSM from Poland living with 
both HCV and HIV [3–5].
A phylogenetic analysis showed that 28 of the 31 sequences 
containing a M28V substitution belonged to a single, large 
cluster with a small genetic distance threshold (<3%), repre-
senting approximately one-third of all newly diagnosed infec-
tions (for methods, see Supplementary Data; Figure 1). This 
high M28V prevalence can be explained by a founder effect 
(ie, the occurrence of an amino acid substitution in high fre-
quency in a particular population). Our M28V cluster could 
be subdivided into 2 sub-clusters, 1 of which contained just 
the M28V variant. In the other sub-cluster, in addition to the 
M28V substitution, several other NS5A RAS were observed: 
for example, NS5A H58P, A62E, and even Y93H (Figure  1). 
In 16 of the 28 M28V-containing sequences, the M28V RAS 
occurred as a pattern with variants H58P and A62E. Although 
these RAS are not considered to be clinically relevant in HCV 
genotype 1a, the high prevalence of the combination supports 
a founder effect. The M28V RAS was already present in sam-
ples obtained in 2013–2014, which was before the widespread 
use of DAA therapy in the Netherlands, strongly suggesting 
that this RAS occurred and spread naturally in HCV 1a viruses 
rather than as the result of selective pressure of DAA therapy. 
We could not identify any association towards a RAS pattern 
and geographic location, or with patient demographics, such 
as HIV status.
In vitro data previously showed that the M28V substi-
tution lowers the susceptibility of HCV genotype 1a to the 
NS5A inhibitors ombitasvir (58-fold change), daclatasvir, and 
pibrentasvir (<2.5-fold change) [6]. In addition, there is no 






/cid/article/71/8/e215/5735665 by guest on 26 February 2021
e216 • cid 2020:71 (15 October) • BRIEF REPORT
of velpatasvir. Furthermore, the M28V substitution proved to 
decrease the cure rates of chronic HCV genotype 1a when 
treated with grazoprevir and elbasvir [1, 6–8]. Luckily, the 
M28V substitution or a combination of RAS including 
the M28V substitution did not affect the treatment out-
come among patients with a recently acquired HCV infec-
tion who were treated with a shortened 8-week regimen of 
grazoprevir and elbasvir [2]. Currently, there are no other re-
ports that discuss the clinical implication of the RAS pattern 
M28V+H58P+A62E (+Y93H). Nevertheless, the Y93H sub-
stitution as a singleton confers high-level (>100 fold-change) 
resistance to NS5A inhibitors, such as daclatasvir, elbasvir, 
ledipasvir, and velpatasvir, and low (<10 fold-change) resist-
ance to pibrentasvir in vitro [9].
The transmission of RAS-carrying viruses has been de-
scribed previously, although the transmission of an NS5A RAS 
in such a large cluster has not been reported before. Previous 
transmission of the M28V RAS was described among 5 MSM 
in France [10]. Additionally, the NS3 RAS V36M and, in par-
ticular, the Q80K were reported to be more prevalent among 
MSM living with both HCV and HIV, in whom the Q80K 
occurred in several clusters [5, 11, 12]. The presence of the 
Q80K had large clinical implications, since the susceptibility 
to the NS3 protease inhibitor simeprevir was lowered in geno-
type 1a patients. Therefore, clinicians were advised to analyze 
the presence of Q80K prior to simeprevir treatment among 
genotype 1a–infected patients. Although pibrentasvir- and 
velpatasvir-containing DAA regimens are also highly effective 
against viruses with RAS, caution remains required. Firstly, 
the availability of these DAA regimens may differ geograph-
ically. Secondly, outbreaks of HCV infections and transmis-
sion to sex or needle-sharing partners continue to occur. Our 
observation illustrates that the transmission of DAA-resistant 
variants can continue to occur over a prolonged period, ir-
respective of the broad rollout of DAA therapy. This may 
be partly explained by the persistence of highly fit, NS5A-
resistant viruses in patients.
Currently, only 5 million of the total 71 million HCV-
infected individuals have been treated [13]. The spread of 
RAS-containing viruses may, in case they affect local cure rates, 
jeopardize global HCV elimination efforts. With a further 
rollout of DAA therapy on a global scale, surveillance for the 
spread of RAS is highly recommended [14]. In cases of signif-
icant transmission rates of clinically relevant RAS-containing 
viruses, targeted precautions can then be taken.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
Figure 1. Phylogenetic analysis of a concatenated NS5A and NS5B alignment showed clusters including 28 MSM (n = 27 living with HIV; n = 1 living without HIV). Of 
the individuals in this cluster, 96% harbored an NS5A M28V–containing variant. All patients in this cluster treated with an NS5A-inhibitor (grazoprevir and elbasvir for 8 
weeks) obtained a sustained virologic response. The sequences depicted with green were collected prior to the massive direct-acting antiviral therapy uptake in 2015, and 
the sequences depicted with blue were collected in the years thereafter. The cluster had a bootstrap value and Shimodaira Hasegawaa–like approximate likelihood ratio of 
>90 and a genetic distance threshold of <3%. For methods, see Supplementary Materials. 
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